Recent News

Restart of Alferon production should drive revenues and earnings in the medium-term

Midtown Partners initiates coverage of Hemispherx Biopharma (HEB) with a Strong Buy rating and a price target of $1.40 (500+% upside). Analysts Alec Jaslow and William Relyea believe the company’s Alferon N Injection drug has potential to take market share from current treatments for Refractory/Recurring HPV genital warts with its advantages which include less side […]

Midtown Partners Initiates Coverage of NanoViricides with a Strong Buy – High Risk Rating.

Midtown Partners initiates coverage of NanoViricides, Inc with a Strong Buy rating with a price target of $5.30. Analysts Alec Jaslow and William Relyea believe the company has a unique platform technology that targeting a number of large market viral diseases, especially important is Complicated Hospitalized Influenza.

Midtown Partners Expands Research Team With Hire Of New Analyst Covering Resource Optimization And Sustainability Sector

New York, NY, February 3 (NYSE MKT: IGC) — Midtown Partners & Co., LLC (Midtown) is pleased to announce the addition of Michael Legg as a director and a senior equity research analyst covering small capitalization stocks in the Resource Optimization and Sustainability sector. Mr. Legg will be based in New York and report to […]

Midtown Partners Initiates Coverage on Marathon Patent Group with a Strong Buy Rating and a price target of $16.73

Midtown Partners initiates coverage on Marathon Patent Group with a Strong Buy rating and a price target of $16.73. Analysts Alec Jaslow and William Relyea believe the company has a compelling patent monetization strategy, strong foothold within the industry, and a favorable long-term outlook; which should provide upside to the share price.